Important common drug 'out of stock' across Scotland for months

PATIENTS in Scotland who take a commonly prescribed antidepressant could be affected by a medicine shortage expected to last until later this year.
NHS Scotland has issued a medicines supply notice warning that venlafaxine 75mg immediate-release tablets are expected to remain unavailable until November.
The medication is used to treat depression and can also be prescribed for anxiety, panic attacks and some menopause symptoms.
According to guidance published by NHS Scotland, prescribers have been advised not to start any new patients on the 75mg immediate-release tablets while supplies remain limited.
READ MORE: Secrecy row as SNP Government refuses to name 13 firms banned under genocide policy
The shortage only affects the immediate-release version of the medication, which is normally taken twice daily.
Alternative formulations, including modified-release venlafaxine capsules in 37.5mg, 75mg and 150mg strengths, remain available and are expected to be used to help meet demand.
Venlafaxine belongs to a group of antidepressants known as serotonin-noradrenaline reuptake inhibitors (SNRIs).
The medicine works by increasing levels of serotonin and noradrenaline in the brain and is commonly used to help reduce symptoms of depression and anxiety.
The NHS Scotland supply notice has been circulated to pharmacies and healthcare professionals across the country.
The warning follows a Tier 2 medium-impact supply alert issued by the Department of Health and Social Care.
READ MORE: Reform UK MSP accidentally backs SNP call for further devolution to Scotland
Health officials have stressed that guidance has been provided to healthcare professionals on managing patients affected by the shortage and on switching suitable patients to alternative formulations where appropriate.
A Department of Health and Social Care spokesperson said: "We are aware of issues with Venlafaxine 75mg immediate release tablets affecting some suppliers.
"We are working closely with all suppliers to resolve the problem, speed up deliveries, and ensure patients can continue to access their medicine.
"We have issued comprehensive guidance on how to manage patients affected by this shortage, including advice on using other types and strengths of the medicine which remain available."
Patients are being advised not to stop taking prescribed medication without first speaking to their GP, pharmacist or healthcare professional.
Share

* Venlafaxine 75mg immediate-release tablets are expected to remain unavailable until November in Scotland.
* The shortage affects only the immediate-release version of the medication.
* The medication treats depression, anxiety, panic attacks, and some menopause symptoms.
* Prescribers were advised not to start new patients on the 75mg immediate-release tablets while supplies are limited.
* Alternative formulations, including modified-release venlafaxine capsules in 37.5mg, 75mg, and 150mg strengths, remain available.
* Venlafaxine is classified as a serotonin-noradrenaline reuptake inhibitor (SNRI).
* Guidance was issued to healthcare professionals on managing patients and switching to alternative formulations.
* The warning followed a Tier 2 medium-impact supply alert from the Department of Health and Social Care.

A shortage affecting venlafaxine 75mg immediate-release tablets is expected to last until November in Scotland, as warned by NHS Scotland. This medication is used to treat depression, anxiety, panic attacks, and some menopause symptoms. Prescribers have been advised not to start new patients on the 75mg immediate-release formulation while supplies are limited. The shortage specifically affects the immediate-release version, which is typically taken twice daily. Alternative formulations of venlafaxine, including modified-release capsules in 37.5mg, 75mg, and 150mg strengths, remain available to meet patient demand. Health officials have provided guidance on managing patients affected by the shortage and switching to alternative treatments where appropriate. The Department of Health and Social Care is working with suppliers to resolve the supply issue and ensure continued access to medication. Patients are advised not to discontinue prescribed medication without consulting a healthcare professional.

The situation reveals a tension between pharmaceutical supply chains, clinical guidelines, and patient access during periods of constrained availability. The restriction focuses narrowly on one specific dosage form (immediate-release), forcing a management response centered on alternatives rather than outright cessation of treatment. This highlights the systemic vulnerability inherent in relying on specific manufacturing streams for essential medications. When scarcity is introduced, the system defaults to procedural mitigation—guiding professionals toward existing, available options—rather than simply pausing care. The implication is that the therapeutic efficacy and safety of venlafaxine can be maintained through formulation switching, suggesting resilience in the pharmacological action itself, though access logistics are clearly fragile. The pattern observed is a shift from supply-focused panic to operationalized clinical flexibility, managed through layered communication from government bodies to frontline providers. What happens when demand outstrips all available alternatives? How reliably do these alternative formulations absorb the necessary therapeutic weight across diverse patient profiles?

Important common drug 'out of stock' across Scotland for months

Facts Only

Executive Summary

Full Take

Important common drug 'out of stock' across Scotland for months

Facts Only

Executive Summary

Full Take